This probably needs to be moved to Problems with Vaccines Past and Present.
That having been said, China that initially denied they were the location where the virus was first discovered in animals, then tried to downplay it and then told the WHO there was no evidence of animal to human transmission, and then when courageous whistle blowers sounded the alarm they silenced its internal critics, then in a worldwide public relations move suddenly developed multiple vaccines that they rolled out to the rest of the world.................yet are reluctant to give it to their own population first.
In a nutshell, that should be all one needs to know to make an informed decision about getting/taking the Chinese versions until they have been thoroughly vetted. Unfortunately for some, common sense tends to take a back seat to panic. or those who subscribe to.......................the best vaccine you can get...........is the one you can get lol.
China has approved a another COVID-19 vaccine for emergency use, adding a fifth shot to its arsenal
abcnews.go.com
Respectfully,
Playacaribe2
Here you can see how the DR fares with:
Duke Global Health Innovation Center - COPYRIGHT 2020 DUKE UNIVERSITY
See our COVID Vaccine Procurement research
See our COVID Vaccine Manufacturing research
Current models predict that there will not be enough vaccines to cover the world's population until
2023 or
2024. Manufacturing capacity can be expanded with targeted investment but only to an extent and it will remain a rate limiter. See our COVID manufacturing data here:
https://launchandscalefaster.org/covid-19/vaccinemanufacturing.
15.4 BILLION DOSES RESERVED
Despite this public commitment to equity, individual countries are incentivized to purchase as many vaccine doses (and from as wide a pool of candidates) as possible in order to increase their chances of covering their population. So far, confirmed purchases cover 8.8 billion doses, with another 6.6 billion doses currently under negotiation or reserved as optional expansions of existing deals.
HIGH-INCOME COUNTRIES ARE HEDGING THEIR BETS WHILE LOW-INCOME COUNTRIES ARE LEFT OUT
These direct deals made by high-income (and some middle-income) countries result in a smaller piece of the pie available for equitable global allocation. This pattern results in a majority of vaccines going to high-income countries and fewer doses available for low- and middle-income countries and for equity-focused partnerships like COVAX.
While this makes sense from the perspective of an individual country, it leads to deep inequities in terms of global allocation. While some middle- and lower-middle income countries are represented here with direct deals, none of them have enough to vaccinate their entire populations. At the same time, Canada has purchased enough to vaccinate its population five times over. (Again, it is important to remember that not all of these vaccines will necessarily receive approval and move to market.)
CEPI, one of the COVAX founding partners, is negotiating with self-financing countries to ensure that, once a certain percentage of their population has been vaccinated, a percentage of the doses secured through bilateral deals would be shared through the COVAX Facility. These negotiations are ongoing; however, high-income countries have little incentive to share from their advance purchase stock.
The first purchases were made by the US and the UK, in May 2020, of the Oxford-AstraZeneca vaccine. These were quickly followed by a slate of purchases by high-income and some middle-income countries and, by the end of summer 2020, the UK, EU countries, and Canada had purchased enough doses through advance market commitments to cover more than their entire populations. The first purchases for low-income countries came in January 2021, through the African Union’s pooled procurement approach. Many countries in Latin America, Africa, and Asia still have not yet been able to purchase enough vaccine.
launchandscalefaster.org
VACCINE MAKERS PROJECT A GLOBAL TOTAL OF 12 BILLION DOSES OF COVID-19 VACCINE IN 2021
Our analysis of 2021 projections from Covid-19 vaccine makers indicates that more than 12 billion doses could be produced this year. It is important to remember that this total is a sum of projections from vaccine developers and may include optimistic assumptions.
Assuming the market is primarily 2-dose vaccines (Janssen and CanSino are the only 1-dose vaccines currently on the market), about 11 billion doses are needed to vaccinate 70 percent of the world’s population. This is frequently seen as the threshold to approach herd immunity, the level of vaccination coverage that limits spread and protects those who are unable to be vaccinated from infection.
PRODUCTION CAPACITY FOR 2021 VARIES WIDELY AMONG VACCINES AND VACCINE PLATFORMS
To meet the global total of more than 12 billion doses projected in 2021, production will need to increase on a scale we have not seen before. The capacity expansion is not evenly spread across vaccine makers, though. The 2021 supply will be dominated by Oxford-AstraZeneca, Pfizer-BioNTech, and Novavax (which is still awaiting regulatory review).
launchandscalefaster.org
launchandscalefaster.org
Brasil, México y Colombia, los países que recibirán más vacunas del programa Covax
Mientras que continúan llegando poco a poco vacunas contra el covid-19 a algunos países de Latinoamérica, la región aún espera la llegada de un importante | Latinoamérica | CNN
cnnespanol.cnn.com
«Hay más de 100 países que no han aplicado ni una sola vacuna», reclama México ante la ONU
www.foxnews.com
coronavirus.jhu.edu
www.worldometers.info
www.cnn.com
